金斯瑞(1548.HK)拉昇漲超18% 子公司獲高瓴2.75億美元入股
格隆匯8月23日丨金斯瑞(1548.HK)拉昇漲超18%至37.15港元,市值779億港元。近日,金斯瑞生物科技發佈公吿,高瓴擬以2.75億美元入股子公司Probio Cayman(蓬勃生物)。其中,蓬勃生物同意出售3億股A類優先股,總代價約為1.5億美元。同時,還有蓬勃生物的認股權證,以在協議完成時,高瓴以約1.25億美元的總代價購買約1.89億股蓬勃生物股份。若1.25億美元認股權證全部實施,蓬勃生物股權結構中,高瓴持股比例將調整為20.68%,金斯瑞持股66.19%,員工持股13.13%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.